![Author's Photo](https://d1b6lhn2ymmy1x.cloudfront.net/journalist-headshots/biopharma/bell-jacob-square-600x600.jpg)
Jacob Bell
Senior Reporter | @realjacobbellJacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
1590 articles by Jacob Bell
-
Leqembi voted down by European regulators
July 26, 2024 -
Sanofi’s immunology bet starts to pay off
July 25, 2024 -
Biogen, Sage tremor drug fails key trial
July 24, 2024 -
Ionis plots next steps for Angelman drug Biogen passed on
July 22, 2024 -
Asceneuron raises another $100M for Alzheimer’s drug development
July 16, 2024 -
Pfizer thinks it found its obesity pill
July 11, 2024 -
Amylyx, with GLP-1 buy, doubles down on blood sugar drugs
July 10, 2024 -
UniQure stock surges on data for Huntington’s gene therapy
July 9, 2024 -
Lilly to buy Morphic in $3B bet on inflammation drug
July 8, 2024 -
CureVac cuts jobs, licenses out vaccines to GSK
July 3, 2024 -
These microscopic tunnels are a goldmine for new medicines
June 27, 2024 -
Syncona melds two gene therapy biotechs for better shot at new nervous system treatments
June 17, 2024 -
Lilly Alzheimer’s drug gets unanimous backing of FDA panel
June 10, 2024 -
After ‘sobering’ FDA panel, psychedelics supporters wonder what’s next
June 7, 2024 -
FDA panel votes against MDMA therapy for PTSD, citing muddy data and safety concerns
June 4, 2024 -
FDA staff outline shortcomings of Lykos data for MDMA therapy
May 31, 2024 -
Orna, a circular RNA specialist, acquires a buzzy startup
May 23, 2024 -
Forbion-backed biotech Progentos debuts with $65M for MS drug
May 20, 2024 -
Biogen, Ionis shelve ALS drug following study failure
May 16, 2024 -
Eisai sets new revenue target for Alzheimer’s drug Leqembi
May 15, 2024 -
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
May 13, 2024 -
FDA sets date for advisory meeting on Lilly’s closely watched Alzheimer’s drug
May 7, 2024 -
Gossamer sells rights to drug it hopes can rival a new Merck therapy
May 6, 2024 -
Reunion raises over $100M to build a better psychedelic drug
May 2, 2024 -
Deciphera to sell for $2.4B, adding to upswing in biopharma M&A
April 29, 2024